Improve precision medicine for kidney cancer in people of African descent
Official title: Improve precision medicine for renal cell carcinoma patients of African ancestry through computational and functional genomics
Funded at Sloan-Kettering Inst Can Research · NIH-11433340 · Data updated 2026-11-12
A research project will explore why kidney cancer affects people of African ancestry differently and how to use genomics to guide better treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | September 1, 2026 |
| Project end | August 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $690,977 |
| NIH project number | 1R01CA315216-01 |
| Project ID | NIH-11433340 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with renal cell carcinoma, especially those of African ancestry, who may benefit from ancestry-specific biomarker discoveries and targeted therapies.
✕Less likely to help
Patients with RCC subtypes or genetic profiles not identified as benefiting from the new biomarkers or therapies studied in this project.
What this research studies
This project focuses on renal cell carcinoma in patients of African ancestry, aiming to understand distinct tumor genetics and identify biomarkers that can guide therapy. It combines computational analyses of big genomic data with laboratory work to uncover actionable targets that current tests might miss. The work seeks to improve classification of cancer subtypes and enable more accurate, personalized treatment options for AFR-associated RCC.
Why it matters
Potential benefit: If successful, the project could lead to more accurate diagnoses and personalized treatments for kidney cancer in people of African ancestry.
How similar studies have gone: Previous studies have shown that ancestry-specific tumor genetics can reveal new therapeutic targets, though much remains unexplored for AFR-associated RCC.
Where this research is happening
-
Sloan-Kettering Inst Can Research
New York, United States Active
Researchers
- Principal investigator: Carrot-Zhang, Jian — Sloan-Kettering Inst Can Research
- Study coordinator: Carrot-Zhang, Jian
Related research
Other NIH-funded projects on the same topics.
-
Understanding how kidney cancer spreads to bone and how to fight it
A patient-focused look at how clear cell renal cell carcinoma spreads to bone and how new treatments might help people with advanced disease.
-
Engineering immunogenic cell death to boost melanoma and kidney cancer therapy
This grant supports research aimed at making melanoma and kidney cancer cells die in a way that triggers a stronger immune response in patients.
-
Prognostic test to predict metastasis in clear cell kidney cancer
A new 12-marker biomarker test for people with clear cell renal cell carcinoma may help doctors predict which patients are at higher risk of metastasis.
-
Defining metabolic targets in kidney cancer for new treatments
A cancer-focused project is exploring how kidney cancer uses metabolism so doctors can find new, targeted ways to treat it.
-
Targeting HIF2 in kidney cancer: a new approach for clear cell RCC
A kidney cancer research program tests whether blocking HIF2 can slow or stop tumors in people with clear cell renal cell carcinoma.
-
How mitochondrial activity and cancer spread are affected by tRNA changes in kidney cancer
This project looks at how specific tRNA modifications influence mitochondrial function and the spread of kidney cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.